What Will The Effects of a Standpoint Research Downgrade Be For Bluebird Bio Inc (NDAQ:BLUE) Shares?

June 19, 2017 - By Winifred Garcia

 What Will The Effects of a Standpoint Research Downgrade Be For Bluebird Bio Inc (NDAQ:BLUE) Shares?

Investors sentiment decreased to 1.29 in Q4 2016. Its down 0.19, from 1.48 in 2016Q3. It turned negative, as 33 investors sold bluebird bio Inc shares while 51 reduced holdings. 30 funds opened positions while 78 raised stakes. 45.73 million shares or 4.13% more from 43.91 million shares in 2016Q3 were reported.

Geode Cap Mgmt Ltd Liability has invested 0.01% in bluebird bio Inc (NASDAQ:BLUE). Cornerstone Capital Mgmt Ltd has 8,400 shares. Blackrock Fund Advsrs invested in 1.81 million shares. Moreover, Plante Moran Fin Advsrs Llc has 0% invested in bluebird bio Inc (NASDAQ:BLUE). Moreover, Goldman Sachs Group has 0% invested in bluebird bio Inc (NASDAQ:BLUE). Voya Invest Mgmt Ltd Com has invested 0% in bluebird bio Inc (NASDAQ:BLUE). Cam Grp Holdings A S accumulated 3,225 shares. Gam Ag holds 0.03% or 30,900 shares. 157,838 were reported by Blackrock Investment Management Limited Liability Corp. Ny State Common Retirement Fund invested in 142,608 shares or 0.01% of the stock. Private Advisor Group Incorporated Ltd Llc invested 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Cqs Cayman L P owns 41,000 shares. National Bank & Trust Of America De invested in 0% or 134,822 shares. 5.16 million were accumulated by Baillie Gifford. Martingale Asset Ltd Partnership invested in 16,908 shares or 0.01% of the stock.

Bluebird Bio Inc (NDAQ:BLUE) Receives a Downgrade

The Equity Rating of Bluebird Bio Inc (NDAQ:BLUE) rating was lowered by stock analysts at Standpoint Research from the previous “Buy” rating to a “Reduce” rating in an analyst note released on 16 June.

Investors sentiment decreased to 1.29 in Q4 2016. Its down 0.19, from 1.48 in 2016Q3. It turned negative, as 33 investors sold bluebird bio Inc shares while 51 reduced holdings. 30 funds opened positions while 78 raised stakes. 45.73 million shares or 4.13% more from 43.91 million shares in 2016Q3 were reported.

Geode Cap Mgmt Ltd Liability has invested 0.01% in bluebird bio Inc (NASDAQ:BLUE). Cornerstone Capital Mgmt Ltd has 8,400 shares. Blackrock Fund Advsrs invested in 1.81 million shares. Moreover, Plante Moran Fin Advsrs Llc has 0% invested in bluebird bio Inc (NASDAQ:BLUE). Moreover, Goldman Sachs Group has 0% invested in bluebird bio Inc (NASDAQ:BLUE). Voya Invest Mgmt Ltd Com has invested 0% in bluebird bio Inc (NASDAQ:BLUE). Cam Grp Holdings A S accumulated 3,225 shares. Gam Ag holds 0.03% or 30,900 shares. 157,838 were reported by Blackrock Investment Management Limited Liability Corp. Ny State Common Retirement Fund invested in 142,608 shares or 0.01% of the stock. Private Advisor Group Incorporated Ltd Llc invested 0.01% of its portfolio in bluebird bio Inc (NASDAQ:BLUE). Cqs Cayman L P owns 41,000 shares. National Bank & Trust Of America De invested in 0% or 134,822 shares. 5.16 million were accumulated by Baillie Gifford. Martingale Asset Ltd Partnership invested in 16,908 shares or 0.01% of the stock.

bluebird bio Inc (NASDAQ:BLUE) Ratings Coverage

Among 2 analysts covering Bluebird Bio Inc (NDAQ:BLUE), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Bluebird Bio Inc has $112 highest and $110 lowest target. $111’s average target is -1.11% below currents $112.25 stock price. Bluebird Bio Inc had 3 analyst reports since May 30, 2017 according to SRatingsIntel. BTIG Research maintained bluebird bio Inc (NASDAQ:BLUE) rating on Thursday, June 1. BTIG Research has “Buy” rating and $112 target. The firm has “Reduce” rating given on Friday, June 16 by Standpoint Research. Standpoint Research initiated it with “Buy” rating and $110 target in Tuesday, May 30 report.

About 222,731 shares traded. bluebird bio Inc (NDAQ:BLUE) has risen 112.34% since June 19, 2016 and is uptrending. It has outperformed by 95.64% the S&P500.

Investors wait bluebird bio Inc (NASDAQ:BLUE) to report on August, 2. its quarterly earnings Wall Street analysts expect $-1.73 EPS, down $0.14 or 8.81 % from last year’s $-1.59 same quarter earnings. bluebird bio Inc’s Wall Street analysts see 2.98 % negative EPS growth, taking into account the $-1.68 EPS reproted in the previous quarter,

bluebird bio, Inc. is a clinical-stage biotechnology company. The company has market cap of $4.53 billion. The Firm is focused on developing gene therapies for severe diseases and cancer. It currently has negative earnings. With its lentiviral gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas.

More notable recent bluebird bio Inc (NASDAQ:BLUE) news were published by: Businesswire.com which released: “bluebird bio Appoints John O. Agwunobi, MD and Douglas A. Melton, Ph.D. to …” on June 08, 2017, also Nasdaq.com with their article: “bluebird bio Reaches Analyst Target Price” published on June 07, 2017, Fool.com published: “Why bluebird bio Inc Flew Higher Today” on June 06, 2017. More interesting news about bluebird bio Inc (NASDAQ:BLUE) were released by: Fool.com and their article: “Why bluebird bio Inc. Flew Higher Again Today” published on June 07, 2017 as well as Marketwatch.com‘s news article titled: “UPDATE: Bluebird Bio stock rises 7.4% on positive data from ongoing early …” with publication date: June 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.